PremiumCompany AnnouncementsZentalis Pharmaceuticals Announces New Study for Azenosertib Zentalis presents updated clinical data on azenosertib Zentalis to reduce workforce by 40% in business restructuring PremiumThe FlyZentalis appoints Eastland as CEO, Bruns as CMO, Myers as Chairperson Zentalis Pharmaceuticals Announces New Leadership and Strategy Shift Zentalis clinical hold resolution came ‘no strings attached,’ says Oppenheimer PremiumThe FlyQualcomm downgraded, Eli Lilly upgraded: Wall Street’s top analyst calls Wedbush upgrades Zentalis to Neutral on valuation post selloff Zentalis price target raised to $10 from $9 at Stifel